Marketing of unproven stem cell–based interventions: A call to action
Douglas Sipp(Keio University Hospital), Timothy Caulfield(University of Alberta), Jane Kaye(University of Oxford), Jan Barfoot(MRC Centre for Regenerative Medicine), Clare Blackburn(MRC Centre for Regenerative Medicine), Sarah Chan(University of Edinburgh), Michele De Luca(University of Modena and Reggio Emilia), Alastair Kent(Queen Mary University of London), Christopher McCabe(University of Alberta), Megan Munsie(The University of Melbourne), Margaret Sleeboom‐Faulkner(University of Sussex), Jeremy Sugarman(Johns Hopkins University), Esther van Zimmeren(University of Antwerp), Amy Zarzeczny(University of Regina), John E. J. Rasko(The University of Sydney)
Cited by 197Open Access
Abstract
Commercial promotion of unsupported therapeutic uses of stem cells is a global problem that has proven resistant to regulatory efforts. Here, we suggest a coordinated approach at the national and international levels focused on engagement, harmonization, and enforcement to reduce the risks associated with direct-to-consumer marketing of unproven stem cell treatments.
Related Papers
No related papers found
Powered by citation graph analysis